Form 4: Bicara COO Sells Shares Under 10b5-1 Plan

Bicara Therapeutics' President and COO, Ryan Cohlhepp, exercised stock options and subsequently sold 12,500 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Ryan Cohlhepp, President and COO, and a Director of Bicara Therapeutics Inc. (BCAX), reported transactions on October 15, 2025.
• Cohlhepp exercised stock options to acquire 8,000 shares of common stock at an exercise price of $3.7898 per share.
• Immediately following the option exercise, he sold a total of 12,500 shares of common stock.
• The sales consisted of 8,000 shares and 4,500 shares, both at a weighted average price of $18.1554 per share, with prices ranging from $18.00 to $18.34.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
• Following these transactions, Cohlhepp beneficially owns 198,141 shares of common stock directly.
• He also retains 157,334 stock options, which vest in sixteen equal quarterly installments following August 8, 2023.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling, even though it was pre-planned under a Rule 10b5-1 plan. While the plan mitigates the immediate negative signal, a reduction in executive ownership is generally not viewed as a strong positive.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not reactive sale.
• The exercise of options at $3.7898 and subsequent sale at a weighted average price of $18.1554 demonstrates a significant profit for the insider on the exercised shares.

Negatives

• A key executive, the President and COO, reduced his direct beneficial ownership of common stock by 12,500 shares.
• Insider selling, even if planned, can sometimes be perceived negatively by the market as it reduces management's direct equity stake.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the insider selling as a signal regarding the company's future prospects or valuation, potentially leading to negative sentiment or selling pressure.
• Employees: No direct impact mentioned, but executive share sales can sometimes affect morale if perceived negatively.

Key Dates

Recommendation

While the insider selling by the President and COO is a notable event, it was conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests it was not based on new, undisclosed material information. The executive still retains a substantial number of shares and options. Investors should monitor future filings and company performance, but this single planned transaction does not warrant an immediate 'sell' recommendation without further negative catalysts. A 'hold' position is prudent to observe broader market and company-specific developments.

Keywords

Bicara Therapeutics, BCAX, Ryan Cohlhepp, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Biotechnology, Executive Compensation